The Institute for Cancer Research, London, has released a report looking at cancer drug delivery in the NHS and the rate of drug development across different types of cancer. ‘Patent to Patient’ analysed the regulatory regime and found that NHS patients are waiting longer for new cancer drugs because of delays in taking them through clinical trials and getting them approved for use.
About Mark Jefferies, Chief of University Research Liaison at Rolls-Royce
About Dr Steven Harris, Head of External Partnerships and Brokering at BAE Systems
About Dr Damian Kelly, Head of Global Research & Development
About Dr Matt Ball, Chief Scientist and Head of Academic Liaison at Thales